LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company (LLY) Business News

Track Eli Lilly and Company in real time with a live news feed covering Eli Lilly and Company stock news, official press releases, company announcements, and an archive of historical Eli Lilly and Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
2:30 PM | Saturday | Jun 6, 2026 PRNewsWire

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

News Thumbnail
9:30 AM | Tuesday | Jun 2, 2026 PRNewsWire

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

News Thumbnail
8:01 AM | Sunday | May 31, 2026 PRNewsWire

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

News Thumbnail
6:45 AM | Thursday | May 28, 2026 PRNewsWire

Foundayo and Zepbound now covered for millions of Americans

News Thumbnail
11:15 AM | Wednesday | May 27, 2026 PRNewsWire

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

News Thumbnail
6:45 AM | Tuesday | May 26, 2026 PRNewsWire

Lilly announces three acquisitions to build infectious disease portfolio

News Thumbnail
8:45 AM | Monday | May 25, 2026 PRNewsWire

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

News Thumbnail
10:00 AM | Monday | May 18, 2026 PRNewsWire

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference

News Thumbnail
11:00 AM | Saturday | May 16, 2026 PRNewsWire

Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth

News Thumbnail
7:00 AM | Thursday | May 14, 2026 PRNewsWire

Lilly and UNICEF collaborate to give millions of children a healthier start

News Thumbnail
12:00 PM | Tuesday | May 12, 2026 PRNewsWire

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

News Thumbnail

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

PRNewsWire

2:30 PM | Saturday | Jun 6, 2026

news photo
Loading...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.
1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%) In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.
8%) at 40 weeks, with up to 46% achieving a normal A1C INDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes – common obesity-related conditions.1,2 The findings from TRIUMPH-1 and TRANSCEND-T2D-1 were presented at the American Diabetes Association (ADA) 86th Scientific Sessions, with TRANSCEND-T2D-1 results simultaneously published in The Lancet. "Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos," said Ania Jastreboff, M.D.

Read full article redirect
2:30 PM | Saturday | Jun 6, 2026

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

PRNewsWire

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.
1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%) In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.
8%) at 40 weeks, with up to 46% achieving a normal A1C INDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1,... Read more

Read full article arrow
News Thumbnail
9:30 AM | Tuesday | Jun 2, 2026

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

PRNewsWire

Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL will be highlighted in a late-breaking oral presentation Ajax Therapeutics, which Lilly has agreed to acquire, will present the first clinical data for its first-in-class type II JAK2 inhibitor for patients with myelofibrosis who have been failed by a type I JAK2 inhibitor Kelonia Therapeutics, which Lilly has agreed to acquire, will present additional correlative clinical data for its in vivo CAR-T program in patients with multiple myeloma  INDIANAPOLIS, June 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) Annual Meeting, taking place June 11-14 in Stockholm, Sweden. Data to be... Read more

Read full article arrow
News Thumbnail
8:01 AM | Sunday | May 31, 2026

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

PRNewsWire

Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be published in the New England Journal of Medicine and simultaneously presented during the Plenary Session at the 2026 ASCO Annual Meeting INDIANAPOLIS, May 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) with selpercatinib... Read more

Read full article arrow
News Thumbnail
6:45 AM | Thursday | May 28, 2026

Foundayo and Zepbound now covered for millions of Americans

PRNewsWire

CVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicine INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance.

Read full article arrow
News Thumbnail
11:15 AM | Wednesday | May 27, 2026

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

PRNewsWire

INDIANAPOLIS, May 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, will take part in a fireside chat at 3:20 p.m.

Read full article arrow
News Thumbnail
6:45 AM | Tuesday | May 26, 2026

Lilly announces three acquisitions to build infectious disease portfolio

PRNewsWire

Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat Acquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious disease INDIANAPOLIS, May 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transactions advance Lilly's strategy of investing in differentiated technology platforms to address significant health problems.

Read full article arrow
News Thumbnail
8:45 AM | Monday | May 25, 2026

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

PRNewsWire

In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease VERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with markedly lower lifetime risk of coronary heart disease Lilly plans to begin enrolling the Phase 2 clinical study of VERVE-102 by the end of this year INDIANAPOLIS, May 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol (LDL-C)... Read more

Read full article arrow
News Thumbnail
10:00 AM | Monday | May 18, 2026

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference

PRNewsWire

INDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, M.D.

Read full article arrow
News Thumbnail
11:00 AM | Saturday | May 16, 2026

Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth

PRNewsWire

Lilly to provide park and court to the City of Indianapolis as part of its 150th anniversary celebration INDIANAPOLIS, May 16, 2026 /PRNewswire/ -- The Caitlin Clark Foundation, in partnership with Eli Lilly and Company (NYSE: LLY) and Musco Lighting, has opened three new multi-sport community courts across Indianapolis—creating year-round access to safe, high-quality spaces for youth to play. These latest court openings include two courts at Indianapolis Public Schools—Clarence Farrington and Edison School of the Arts—and a public court at the corner of E.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | May 14, 2026

Lilly and UNICEF collaborate to give millions of children a healthier start

PRNewsWire

Six-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countries NEW YORK and INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable disease (NCD) prevention and care for children, reaching over 30 million young people and caregivers across 21 low- and middle-income countries. Marking its 150th anniversary, Lilly is committing $50 million to UNICEF USA, supporting UNICEF's efforts to strengthen primary healthcare systems to better prevent, detect and manage NCDs such as diabetes, congenital heart disease, sickle cell disease and respiratory illness in children and adolescents.

Read full article arrow
News Thumbnail
12:00 PM | Tuesday | May 12, 2026

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

PRNewsWire

Through charitable support of HATCH, United Way Worldwide, United Way of Central Indiana and the Pacers Foundation, the initiative supports efforts to expand access to protein-rich food across communities nationwide, including the creation of infrastructure to deliver an estimated five million meals annually for years to come. INDIANAPOLIS, May 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an initiative to support nationwide nutritious food distribution as part of the company's 150th anniversary, through charitable support of trusted community organizations in the United States.

Read full article arrow
News Thumbnail